Halozyme Therapeutics (HALO +4.4%) moves up after saying results from a Phase 2 study of...

|About: Halozyme Therapeutics, Inc. (HALO)|By:, SA News Editor

Halozyme Therapeutics (HALO +4.4%) moves up after saying results from a Phase 2 study of rHuPH20, a prandial insulin, met its primary endpoint for blood sugar measurement in patients with Type 1 diabetes. Additionally, data from the study further indicated that rHuPH20 also reduced postprandial glycemic excursions, as well as significantly reduced hypoglycemic events.